{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:29:41Z","timestamp":1787617781086,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s13555-023-00909-z","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T10:12:35Z","timestamp":1678097555000},"page":"1039-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8341-7300","authenticated-orcid":false,"given":"Chika","family":"Ohata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikazu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"909_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ijd.14864","volume":"59","author":"S AlQassimi","year":"2020","unstructured":"AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis\u2014comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59:566\u201371. https:\/\/doi.org\/10.1111\/ijd.14864.","journal-title":"Int J Dermatol"},{"key":"909_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/jdv.13891","volume":"31","author":"P Fleming","year":"2017","unstructured":"Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31:798\u2013807. https:\/\/doi.org\/10.1111\/jdv.13891.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"909_CR3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/jid.2013.508","volume":"134","author":"EA Dowlatshahi","year":"2014","unstructured":"Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134:1542\u201351. https:\/\/doi.org\/10.1038\/jid.2013.508.","journal-title":"J Invest Dermatol"},{"key":"909_CR4","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1111\/jdv.17621","volume":"36","author":"C Ohata","year":"2022","unstructured":"Ohata C, Kanai Y, Murotani K, Kitabayashi H, Imafuku S. Difference in health-related quality of life between anxiety and depressive symptoms in Japanese patients with plaque psoriasis: the ProLOGUE study. J Eur Acad Dermatol Venereol. 2022;36:e57\u20139. https:\/\/doi.org\/10.1111\/jdv.17621.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"909_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jtumed.2021.02.008","volume":"16","author":"RS Bakar","year":"2021","unstructured":"Bakar RS, Jaapar SZS, Azmi AF, Aun YC. Depression and anxiety among patients with psoriasis: a correlation with quality of life and associated factors. J Taibah Univ Med Sci. 2021;16:491\u20136. https:\/\/doi.org\/10.1016\/j.jtumed.2021.02.008.","journal-title":"J Taibah Univ Med Sci"},{"key":"909_CR6","doi-asserted-by":"publisher","first-page":"109780","DOI":"10.1016\/j.jpsychores.2019.109780","volume":"124","author":"JM Mart\u00ednez-Ortega","year":"2019","unstructured":"Mart\u00ednez-Ortega JM, Nogueras P, Mu\u00f1oz-Negro JE, Guti\u00e9rrez-Rojas L, Gonz\u00e1lez-Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: a case-control study. J Psychosom Res. 2019;124:109780. https:\/\/doi.org\/10.1016\/j.jpsychores.2019.109780.","journal-title":"J Psychosom Res"},{"key":"909_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/jocn.15577","volume":"30","author":"CF Pollo","year":"2021","unstructured":"Pollo CF, Miot HA, Matos TDS, et\u00a0al. Prevalence and factors associated with depression and anxiety in patients with psoriasis. J Clin Nurs. 2021;30:572\u201380. https:\/\/doi.org\/10.1111\/jocn.15577.","journal-title":"J Clin Nurs"},{"key":"909_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et\u00a0al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273\u201386. https:\/\/doi.org\/10.1111\/bjd.14493.","journal-title":"Br J Dermatol"},{"key":"909_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jdv.15878","volume":"34","author":"M Masson Regnault","year":"2020","unstructured":"Masson Regnault M, Casta\u00f1eda-Sanabria J, Diep Tran MHT, et\u00a0al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020;34:293\u2013300. https:\/\/doi.org\/10.1111\/jdv.15878.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"909_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jdermsci.2021.01.002","volume":"101","author":"S Imafuku","year":"2021","unstructured":"Imafuku S, Kanai Y, Murotani K, et\u00a0al. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: results from the ProLOGUE study. J Dermatol Sci. 2021;101:185\u201393. https:\/\/doi.org\/10.1016\/j.jdermsci.2021.01.002.","journal-title":"J Dermatol Sci"},{"key":"909_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jdermsci.2022.02.007","volume":"105","author":"S Imafuku","year":"2022","unstructured":"Imafuku S, Ohata C, Okubo Y, et\u00a0al. Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: the ProLOGUE study. J Dermatol Sci. 2022;105:176\u201384. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.02.007.","journal-title":"J Dermatol Sci"},{"key":"909_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jjco\/hyaa028","volume":"50","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Shibata T. Regulatory changes after the enforcement of the new Clinical Trials Act in Japan. Jpn J Clin Oncol. 2020;50:399\u2013404. https:\/\/doi.org\/10.1093\/jjco\/hyaa028.","journal-title":"Jpn J Clin Oncol"},{"key":"909_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092\u20137. https:\/\/doi.org\/10.1001\/archinte.166.10.1092.","journal-title":"Arch Intern Med"},{"key":"909_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2008.06.026","volume":"114","author":"K Kroenke","year":"2009","unstructured":"Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114:163\u201373. https:\/\/doi.org\/10.1016\/j.jad.2008.06.026.","journal-title":"J Affect Disord"},{"key":"909_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3928\/0048-5713-20020901-06","volume":"32","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32:509\u201315. https:\/\/doi.org\/10.3928\/0048-5713-20020901-06.","journal-title":"Psychiatr Ann"},{"key":"909_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"909_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"key":"909_CR18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et\u00a0al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"key":"909_CR19","first-page":"47","volume":"64","author":"S Ikeda","year":"2015","unstructured":"Ikeda S, Shiroiwa T, Igarashi A, et\u00a0al. Developing a Japanese version of the EQ-5D-5L value set. J Natl Inst Public Health. 2015;64:47\u201355.","journal-title":"J Natl Inst Public Health"},{"key":"909_CR20","doi-asserted-by":"publisher","first-page":"adv00422","DOI":"10.2340\/00015555-3712","volume":"101","author":"M Talamonti","year":"2021","unstructured":"Talamonti M, Malara G, Natalini Y, et\u00a0al. Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study. Acta Derm Venereol. 2021;101:adv00422. https:\/\/doi.org\/10.2340\/00015555-3712.","journal-title":"Acta Derm Venereol"},{"key":"909_CR21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.17109","volume":"35","author":"D Tha\u00e7i","year":"2021","unstructured":"Tha\u00e7i D, Soliman AM, Eyerich K, et\u00a0al. Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-na\u00efve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. J Eur Acad Dermatol Venereol. 2021;35:1686\u201391. https:\/\/doi.org\/10.1111\/jdv.17109.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"909_CR22","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","volume":"156","author":"M Augustin","year":"2020","unstructured":"Augustin M, Lambert J, Zema C, et\u00a0al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020;156:1344\u201353. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3617.","journal-title":"JAMA Dermatol"},{"key":"909_CR23","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jdv.15012","volume":"32","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Armstrong AW, Han C, et\u00a0al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018;32:1940\u20139. https:\/\/doi.org\/10.1111\/jdv.15012.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"909_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/09546634.2019.1592096","volume":"31","author":"J Leman","year":"2020","unstructured":"Leman J, Walton S, Layton AM, et\u00a0al. The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. J Dermatolog Treat. 2020;31:213\u201321. https:\/\/doi.org\/10.1080\/09546634.2019.1592096.","journal-title":"J Dermatolog Treat"},{"key":"909_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Gooderham M, de Jong EMGJ, et\u00a0al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018;78:70\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.051.","journal-title":"J Am Acad Dermatol"},{"key":"909_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/09546634.2018.1476654","volume":"30","author":"N Salame","year":"2019","unstructured":"Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. J Dermatolog Treat. 2019;30:135\u201340. https:\/\/doi.org\/10.1080\/09546634.2018.1476654.","journal-title":"J Dermatolog Treat"},{"key":"909_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2340\/00015555-3114","volume":"99","author":"MJ Trib\u00f3","year":"2019","unstructured":"Trib\u00f3 MJ, Turroja M, Casta\u00f1o-Vinyals G, et\u00a0al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Derm Venereol. 2019;99:417\u201322. https:\/\/doi.org\/10.2340\/00015555-3114.","journal-title":"Acta Derm Venereol"},{"key":"909_CR28","first-page":"361","volume":"104","author":"J Koo","year":"2019","unstructured":"Koo J, Ho RS, Thibodeaux Q. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review. Cutis. 2019;104:361\u20135.","journal-title":"Cutis"},{"key":"909_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14740338.2020.1730326","volume":"19","author":"H Iznardo","year":"2020","unstructured":"Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19:365\u201372. https:\/\/doi.org\/10.1080\/14740338.2020.1730326.","journal-title":"Expert Opin Drug Saf"},{"key":"909_CR30","first-page":"44","volume":"13","author":"R Rivera-Oyola","year":"2020","unstructured":"Rivera-Oyola R, Stanger R, Litchman GH, et\u00a0al. The use of brodalumab in three patients with psoriasis and psychiatric comorbidities. J Clin Aesthet Dermatol. 2020;13:44\u20138.","journal-title":"J Clin Aesthet Dermatol"},{"key":"909_CR31","unstructured":"Kyowa Kirin. LUMICEF\u00ae Subcutaneous Injection 210 mg Syringe. Package insert version 4, revised June 2022. In Japanese."},{"key":"909_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1346-8138.15196","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Terui T, Morita A, et\u00a0al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47:201\u201322.","journal-title":"J Dermatol"},{"key":"909_CR33","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1111\/1346-8138.16691","volume":"50","author":"H Saeki","year":"2023","unstructured":"Saeki H, Mabuchi T, Asahina A, et\u00a0al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50:e41\u201368.","journal-title":"J Dermatol"},{"key":"909_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/jdv.13918","volume":"31","author":"D Tha\u00e7i","year":"2017","unstructured":"Tha\u00e7i D, Kimball A, Foley P, et\u00a0al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31:498\u2013506. https:\/\/doi.org\/10.1111\/jdv.13918.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"909_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jpsychores.2017.01.007","volume":"94","author":"P \u0141akuta","year":"2017","unstructured":"\u0141akuta P, Przyby\u0142a-Basista H. Toward a better understanding of social anxiety and depression in psoriasis patients: the role of determinants, mediators, and moderators. J Psychosom Res. 2017;94:32\u20138. https:\/\/doi.org\/10.1016\/j.jpsychores.2017.01.007.","journal-title":"J Psychosom Res"},{"key":"909_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.annder.2019.03.002","volume":"146","author":"A Yang","year":"2019","unstructured":"Yang A, Xin X, Yang W, et\u00a0al. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept. Ann Dermatol Venereol. 2019;146:363\u201371. https:\/\/doi.org\/10.1016\/j.annder.2019.03.002.","journal-title":"Ann Dermatol Venereol"},{"key":"909_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1525\/collabra.128","volume":"4","author":"DE Gustavson","year":"2018","unstructured":"Gustavson DE, du Pont A, Whisman MA, Miyake A. Evidence for transdiagnostic repetitive negative thinking and its association with rumination, worry, and depression and anxiety symptoms: a commonality analysis. Collabra Psychol. 2018;4:13. https:\/\/doi.org\/10.1525\/collabra.128.","journal-title":"Collabra Psychol"},{"key":"909_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ad.2018.05.009","volume":"110","author":"S Gonz\u00e1lez-Parra","year":"2019","unstructured":"Gonz\u00e1lez-Parra S, Daud\u00e9n E. Psoriasis and depression: the role of inflammation. Actas Dermosifiliogr (Engl Ed). 2019;110:12\u20139. https:\/\/doi.org\/10.1016\/j.ad.2018.05.009.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"909_CR39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40257-017-0279-8","volume":"18","author":"N Patel","year":"2017","unstructured":"Patel N, Nadkarni A, Cardwell LA, et\u00a0al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18:613\u201320. https:\/\/doi.org\/10.1007\/s40257-017-0279-8.","journal-title":"Am J Clin Dermatol"},{"key":"909_CR40","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","volume":"31","author":"J Koo","year":"2017","unstructured":"Koo J, Marangell LB, Nakamura M, et\u00a0al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31:1999\u20132009. https:\/\/doi.org\/10.1111\/jdv.14460.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00909-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T16:43:54Z","timestamp":1680108234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00909-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"11 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}